Kalaris Therapeutics Inc
KLRS8.340USD
-0.010-0.12%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
155.98MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Kalaris Therapeutics Inc Unternehmen
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc Informationen
BörsenkürzelKLRS
Name des UnternehmensKalaris Therapeutics Inc
IPO-datumJul 30, 2020
CEOOxtoby (Andrew)
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
Addresse400 Connell Drive
StadtBERKELEY HEIGHTS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07922
Telefon16502492727
Websitehttps://kalaristx.com/
BörsenkürzelKLRS
IPO-datumJul 30, 2020
CEOOxtoby (Andrew)
Führungskräfte von Kalaris Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1519.00%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
+4030.00%
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1519.00%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
+4030.00%
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Umsatzaufteilung
FY2021
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Samsara BioCapital, LLC
69.23%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
Andere
19.68%
Aktionäre
Aktionäre
Anteil
Samsara BioCapital, LLC
69.23%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
Andere
19.68%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
69.70%
Individual Investor
6.43%
Corporation
6.16%
Investment Advisor
4.81%
Hedge Fund
4.35%
Investment Advisor/Hedge Fund
1.42%
Andere
7.12%
Institutionelle Beteiligung
Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
71
14.74M
71.45%
--
2025Q4
153
14.85M
79.41%
+821.65K
2025Q3
193
13.23M
70.72%
-1.05M
2025Q2
227
16.58M
88.66%
+10.64M
2025Q1
234
16.39M
87.75%
+10.95M
2024Q4
237
3.88M
53.28%
-1.58M
2024Q3
243
4.43M
85.21%
-1.20M
2024Q2
253
4.51M
86.91%
-1.04M
2024Q1
252
4.61M
89.02%
-783.99K
2023Q4
254
4.25M
88.46%
-716.47K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Samsara BioCapital, LLC
12.95M
69.23%
+1.50M
+13.10%
Dec 22, 2025
ElevateBio LLC
724.99K
3.88%
--
--
Jun 25, 2025
Ferrara (Napoleone)
504.00K
2.69%
--
--
Jun 25, 2025
F2 MG Ltd
427.31K
2.28%
-1.00
-0.00%
Jun 25, 2025
Tang Capital Management, LLC
418.24K
2.24%
+57.38K
+15.90%
Sep 30, 2025
Invus Public Equities Advisors, LLC
318.26K
1.7%
+35.68K
+12.63%
Sep 30, 2025
The Vanguard Group, Inc.
203.05K
1.09%
+73.21K
+56.39%
Sep 30, 2025
Patel (Samirbhai Chandrakant)
252.00K
1.35%
+252.00K
--
Mar 18, 2025
Woodline Partners LP
241.10K
1.29%
+241.10K
--
Sep 30, 2025
Rezai (Kourous)
203.67K
1.09%
+203.67K
--
Jun 25, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0%
Fidelity Enhanced Small Cap ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Avantis US Equity ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Schwab U.S. Broad Market ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 10, 2025
Merger
23→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 10, 2025
Merger
23→1
